Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Department of Hospital Infection Control, Korea University Guro Hospital, Seoul, Korea.
J Korean Med Sci. 2021 Apr 19;36(15):e110. doi: 10.3346/jkms.2021.36.e110.
Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.
在医护人员接种首剂 2019 冠状病毒病（COVID-19）疫苗后，对他们进行了基于医院的不良事件监测。在两种新平台疫苗（信使 RNA 和腺病毒载体疫苗）中，腺病毒载体疫苗接种者的全身性不良事件发生率显著更高。腺病毒载体疫苗接种者中最常见的不良事件包括疲劳（87.6%比 53.8%）、肌痛（80.8%比 50.0%）、头痛（72.0%比 28.8%）和发热（≥38.0°C，38.7%比 0%），但大多数症状在 2 天内得到缓解。两种 COVID-19 疫苗总体上均安全，且很少发生严重不良事件。
